57 recruiting, 47 completed, 36 active not recruiting, 25 terminated. 93 Phase 1, 93 Phase 2, 19 Phase 3, 8 Early Phase 1, 4 Phase 4.
Follow this condition Literature Review of Metastatic Castration-Resistant Prostate Cancer trials Research Report on Metastatic Castration-Resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 192 | 2027-06-28 | 2026-09-30 |
| Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI - Metastatic Castration-resistant Prostate Cancer | Early Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 15 | 2026-10-01 | 2026-10-01 |
| Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer Zanzalintinib - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Not yet recruiting | Pedro Barata, MD, MSc | 19 | 2026-10-01 | 2026-09-16 |
| Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer SRT-017 - Metastatic Castration-Resistant Prostate Cancer | Early Phase 1 | Recruiting | Affiliated Hospital of Jiangnan University | 18 | 2026-07-30 | 2026-09-01 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer BNT324, Docetaxel, Prednisone/prednisolone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | BioNTech SE | 736 | 2026-04-22 | 2026-10-16 |
| Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer JANX014 - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Janux Therapeutics | 43 | 2026-04-15 | 2026-09-03 |
| ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium Actinium (225Ac) rhPSMA-10.1 - Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | University College, London | 60 | 2026-04-13 | 2026-05-08 |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer Inavolisib, Enzalutamide, Abiraterone - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Hoffmann-La Roche | 100 | 2026-03-11 | 2026-10-08 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617 - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2026-03-03 | 2026-05-15 |
| Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer ETB-DualNK-01, Fludarabine, Cyclophosphamide - Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma | Phase 1 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-11 |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) FG-3246 - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Kyntra Bio | 75 | 2026-02-22 | 2026-08-17 |
| A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy ITC-6146RO - Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer | Phase 1 | Not yet recruiting | IntoCell, Inc | 102 | 2026-02-06 | 2026-02-20 |
| A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer ASP5541, Prednisone - Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 12 | 2026-01-20 | 2026-02-18 |
| A Phase I Trial of A-CAR032 in Participants With mCRPC dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection - Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Recruiting | Shanghai AbelZeta Ltd. | 27 | 2026-01-13 | 2026-10-16 |
| Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors GVV858, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 205 | 2025-12-29 | 2026-10-09 |
| A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) Valemetostat, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Daiichi Sankyo | 60 | 2025-12-03 | 2026-05-15 |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Xaluritamig, Abiraterone acetate, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | Amgen | 750 | 2025-11-28 | 2026-10-20 |
| A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) KTX-2001, KTX-2001 + Darolutamide (NUBEQA®) - Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients | Phase 1 | Recruiting | K36 Therapeutics, Inc. | 144 | 2025-11-21 | 2026-10-20 |
Showing 20 of 196. Sign in to see all of them.
Prostatic Neoplasms (81) · Neoplasms (16) · Neoplasm Metastasis (11) · Breast Neoplasms (5) · Endometrial Neoplasms (5) · Prostatic Neoplasms, Castration-Resistant (5) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Ovarian Epithelial (4) · Colorectal Neoplasms (4) · Ovarian Neoplasms (4) · Prostatic Diseases (4) · Urogenital Neoplasms (4) · Carcinoma, Renal Cell (3) · Genital Neoplasms, Male (3) · Neoplasms by Site (3)
Neoplasms by Site (92) · Genital Diseases (89) · Urogenital Diseases (89) · Urogenital Neoplasms (87) · Male Urogenital Diseases (85) · Neoplasms (85) · Genital Diseases, Male (83) · Genital Neoplasms, Male (80) · Prostatic Diseases (79) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Neoplasms, Glandular and Epithelial (13) · Carcinoma (12) · Neoplasms by Histologic Type (11) · Neoplastic Processes (11)
enzalutamide (32) · Abiraterone Acetate (24) · Prednisone (22) · Docetaxel (15) · abiraterone (15) · olaparib (13) · Pluvicto (11) · cabazitaxel (9) · darolutamide (9) · Prednisolone (8) · Carboplatin (6) · radium Ra 223 dichloride (6) · Nivolumab (5) · Cyclophosphamide (4) · Dexamethasone (4)
AstraZeneca (10) · Amgen (5) · Astellas Pharma Global Development, Inc. (5) · Peking Union Medical College Hospital (5) · Rahul Aggarwal (5) · University of Utah (5) · Bayer (4) · Dana-Farber Cancer Institute (4) · Merck Sharp & Dohme LLC (4) · Novartis Pharmaceuticals (4) · Peter MacCallum Cancer Centre, Australia (4) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Exelixis (3) · Regeneron Pharmaceuticals (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3)
United States (114) · China (41) · United Kingdom (34) · France (30) · Australia (27) · Canada (26) · Spain (26) · Germany (21) · Italy (19) · Netherlands (19) · Belgium (15) · South Korea (15) · Japan (14) · Sweden (13) · Poland (12)
Rahul Aggarwal, MD (6) · Umang Swami, MD (4) · Samuel Denmeade, MD (3) · Fangjian Zhou, M.D. (2) · Fred Saad, MD (2) · Jingsong Zhang, MD, PhD (2) · Noel Clarke, M.D. (2) · Pedro Barata, MD, MSc (2) · Prof Michael Hofman (2)
PMID 36826464, PMID 25683285, PMID 26343110, PMID 28844372, PMID 30227893, PMID 30591354, PMID 31727538, PMID 31774688, PMID 32343890, PMID 32923850, PMID 32955174, PMID 33602696, PMID 34083234, PMID 34168015, PMID 34197212, PMID 34646387, PMID 34789394, PMID 35091440, PMID 35101941, PMID 35110415, PMID 35142815, PMID 35157830, PMID 35229141, PMID 35397952, PMID 35598359, PMID 35898703, PMID 36063830, PMID 36125208, PMID 36210487, PMID 36465905, PMID 36717150, PMID 36735603, PMID 37060432, PMID 37507802, PMID 37714168, PMID 37864592, PMID 37940446, PMID 37963304, PMID 38127780, PMID 38164586, PMID 38319800, PMID 38340349, PMID 38452327, PMID 38593212, PMID 38621400, PMID 38658392, PMID 38926066, PMID 38991752, PMID 39134652, PMID 39327017
2025 (5), 2016 (3), 2023 (3), 2019 (2), 2014 (1), 2015 (1), 2017 (1), 2018 (1), P50CA272391 (1), R01CA229354 (1), R01CA258297 (1), R01MH115043 (1), R44CA278187 (1), ZIAEB000073 (1)